The world’s most valuable pharma company is using its weight loss windfall to fund the next generation of genetic medicine.
Eli Lilly (LLY) announced Monday it has agreed to acquire Orna Therapeutics for up to $2.4 billion in cash. While Lilly dominates the metabolic market (Mounjaro/Zepbound), this deal signals a massive pivot into Immunology and “In Vivo” CAR-T—attempting to solve the manufacturing bottleneck that has plagued cell therapy for a decade.
🔬 THE TECH: WHY “CIRCULAR” MATTERS: Current mRNA therapies (like COVID vaccines) use linear RNA, which degrades quickly. Orna’s proprietary oRNA® technology engineers RNA into a closed loop (circle).
- Stability: With no “ends” for enzymes to grab, circular RNA lasts much longer in the body.
- The Delivery: Paired with custom Lipid Nanoparticles (LNPs), it allows the patient’s own body to become the “manufacturing plant,” generating therapeutic cells inside the patient rather than in a lab.
🎯 THE LEAD ASSET (ORN-252): Lilly is acquiring ORN-252, a CD19-targeting therapy designed for B-cell driven autoimmune diseases (like Lupus).
- The Shift: Traditional CAR-T requires extracting cells, engineering them in a lab, and re-infusing them (complex, expensive).
- The Goal: Orna’s approach is “off-the-shelf”—a simple infusion that reprograms the immune system in vivo.
💰 THE STRATEGY: Lilly is effectively hedging its future.
- Diversification: Moving cash piles from the obesity super-cycle into high-risk, high-reward platforms.
- Deal Flow: This comes just hours after a separate $3.5 billion alliance with Innovent Biologics, confirming that Lilly is aggressively locking in external innovation in 2026.
💡 ANALYST TAKEAWAY: If Orna’s platform works, it democratizes cell therapy. By removing the need for complex “ex vivo” manufacturing, Lilly could potentially treat autoimmune conditions at a scale that current CAR-T therapies can never touch. They aren’t just buying a drug; they are buying a platform that turns the human body into a bioreactor.
👇 Biotech Pros: Is “Circular RNA” the key to finally making cell therapy scalable for mass-market diseases?